The clinical relevance of early anti-adalimumab antibodies detection in rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: A prospective multicentre study

Joint Bone Spine

Volumn 83, Issue 2, 2016, Pages 167-171

  Hoxha, Ariela ^a   Calligaro, Antonia ^a   Tonello, Marta ^a   Ramonda, Roberta ^a   Carletto, Antonio ^b   Paolazzi, Giuseppe ^c   Bortolotti, Roberto ^c   Del Ross, Teresa ^a   Grava, Chiara ^d   Boaretto, Massimo ^d   Favaro, Maria ^a   Teghil, Vera ^a   Ruffatti, Amelia ^a   Punzi, Leonardo ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c SANTA CHIARA HOSPITAL   (Italy)

^d SAN MARTINO HOSPITAL   (Italy)

Author keywords

Ankylosing spondylitis; Anti adalimumab antibodies; Psoriatic arthritis; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; ADALIMUMAB ANTIBODY; CELL NUCLEUS ANTIGEN; DRUG ANTIBODY; METHOTREXATE; PHOSPHOLIPID ANTIBODY; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; ANKYLOSING SPONDYLITIS; ANTIBODY BLOOD LEVEL; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG TREATMENT FAILURE; FEMALE; HUMAN; INJECTION SITE ERYTHEMA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PROSPECTIVE STUDY; PSORIATIC ARTHRITIS; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; URTICARIA; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; EARLY DIAGNOSIS; IMMUNOLOGY; MIDDLE AGED; SPONDYLITIS, ANKYLOSING;

ADALIMUMAB; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; EARLY DIAGNOSIS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING;

EID: 84959569391     PISSN: 1297319X     EISSN: 17787254     Source Type: Journal    
DOI: 10.1016/j.jbspin.2015.04.020     Document Type: Article

References (30)

1. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
2. Weinblatt M.E., Keystone E.C., Furst D.E., et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 2003, 48:35-45.
3. Mease P.J., Gladman D.D., Ritchlin C.T., et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005, 52:3279-3289.
4. van der Heijde D., Schiff M.H., Sieper J., et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009, 68:922-929.
5. de Vries M.K., Brouwer E., van der Horst-Bruinsma I.E., et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009, 68:1787-1788.
6. Bennett A.N., Peterson P., Zain A., et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. Rheumatology 2005, 44:1026-1031.
7. de Vries M.K., Wolbink G.J., Stapel S.O., et al. Inefficacy of infliximab in ankylosing spondylitis is correlated with antibody formation. Ann Rheum Dis 2007, 66:133-134.
8. Wolbink G.J., Vis M., Lems W., et al. Development of anti infliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:711-715.
9. Bartelds G.M., Wijbrandts C.A., Nurmohamed M.T., et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007, 66:921-926.
10. Bartelds G.M., Wolbink G.J., Stapel S., et al. High levels of human anti-human antibodies to adalimumab in a patient not responding to adalimumab treatment. Ann Rheum Dis 2006, 65:1249-1250.
11. Vincent F.B., Morand E.F., Murphy K., et al. Antidrug antibodies to TNF-specific neutralizing agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013, 72:165-178.
12. Calabrese L.H. Molecular differences in anticytokine therapies. Clin Exp Rheumatol 2003, 21:241-248.
13. Aarden L., Ruuls S.R., Wolbink G. Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement. Curr Opin Immunol 2008, 20:431-435.
14. van der Laken C.J., Voskuyl A.E., Roos J.C., et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007, 66:253-256.
15. van Schouwenburg P.A., van de Stadt L.A., de Jong R.N., et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisation. Ann Rheum Dis 2013, 72:104-109.
16. Aletaha D., Neogi T., Silman A.J. et al., 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62:2569-2581.
17. Van der Linden S., Valkendurg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
18. Vasey F.B., Espinoza L.R. Psoriatic arthritis. Spondyloarthropathies 1984, 151-185. Grune and Stratton, Orlando. A. Calin (Ed.).
19. Salvarani C., Pipitone N., Marchesoni A., et al. Recommendations for the use of biologic therapy in the treatment of psoriatic arthritis: update from the Italian Society for Rheumatology. Clin Exp Rheumatol 2011, 29:S28-S41.
20. Van Gestel A.M., Anderson J.J., van Riel P.L., et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis. American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol 1999, 26:705-711.
21. Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumor necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
22. Ruffatti A., Olivieri S., Tonello M., et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008, 6:1693-1696.
23. Cavazzana A., Ruffatti A., Tonello M., et al. An analysis of experimental conditions influencing the anti-beta2-glycoprotein I ELISA assay results. Ann N Y Acad Sci 2007, 1109:484-492.
24. Pengo V., Tripodi A., Reber G., et al. Update of the guidelines for lupus anticoagulant detection. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2009, 7:1737-1740.
25. Bartelds G.M., Krieckaert C.L., Nurmohamed M.T., et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011, 305:1460-1468.
26. Radstake T.R., Svenson M., Eijsbouts A.M., et al. Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1739-1745.
27. Krieckaert C.L., Nurmohamed M.T., Wolbink G.J. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis 2012, 71:1914-1915.
28. Takase K., Horton S.C., Ganesha A., et al. What is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort. Ann Rheum Dis 2014, 73:1695-1699.
29. Hoxha A., Ruffatti A., Grypiotis P., et al. Antinuclear, anti-dsDNA and anti-ENA antibodies in patients affected with rheumatoid arthritis or ankylosing spondylitis during treatment with infliximab. Reumatismo 2006, 58:121-126.
30. Eriksson C., Engstrand S., Sundqvist K.G., et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNFα. Ann Rheum Dis 2005, 64:403-407.